Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association
- PMID: 19478221
- PMCID: PMC2782817
- DOI: 10.1161/STROKEAHA.109.192535
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association
Erratum in
- Stroke. 2010 Sep;41(9):e562
Comment in
-
Expanding recombinant tissue plasminogen activator time window is premature.Stroke. 2009 Nov;40(11):e632; author reply e634-5. doi: 10.1161/STROKEAHA.109.560615. Epub 2009 Oct 1. Stroke. 2009. PMID: 19797699 No abstract available.
-
Guidelines for extending the tissue plasminogen activator treatment window for ischemic stroke.Stroke. 2009 Nov;40(11):e633. doi: 10.1161/STROKEAHA.109.559633. Epub 2009 Oct 1. Stroke. 2009. PMID: 19797700 No abstract available.
Similar articles
-
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.Circulation. 2011 Feb 22;123(7):750-8. doi: 10.1161/CIRCULATIONAHA.110.974675. Epub 2011 Feb 10. Circulation. 2011. PMID: 21311083
-
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22. Stroke. 2016. PMID: 26696642 Review.
-
Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke.Stroke. 2008 Aug;39(8):2388-91. doi: 10.1161/STROKEAHA.107.510917. Epub 2008 Jun 5. Stroke. 2008. PMID: 18535272 Clinical Trial.
-
Guidelines for extending the tissue plasminogen activator treatment window for ischemic stroke.Stroke. 2009 Nov;40(11):e633. doi: 10.1161/STROKEAHA.109.559633. Epub 2009 Oct 1. Stroke. 2009. PMID: 19797700 No abstract available.
-
Role of tissue plasminogen activator in acute ischemic stroke.Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386027 Review.
Cited by
-
The Role of Induced Pluripotent Stem Cells in the Treatment of Stroke.Curr Neuropharmacol. 2024;22(14):2368-2383. doi: 10.2174/1570159X22666240603084558. Curr Neuropharmacol. 2024. PMID: 39403058 Review.
-
Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged.EPMA J. 2024 Aug 29;15(3):415-452. doi: 10.1007/s13167-024-00376-2. eCollection 2024 Sep. EPMA J. 2024. PMID: 39239108 Free PMC article. Review.
-
Metal protoporphyrin-induced self-assembly nanoprobe enabling precise tracking and antioxidant protection of stem cells for ischemic stroke therapy.Smart Med. 2023 Feb 14;2(1):e20220037. doi: 10.1002/SMMD.20220037. eCollection 2023 Feb. Smart Med. 2023. PMID: 39188561 Free PMC article.
-
Critical role of Slc22a8 in maintaining blood-brain barrier integrity after experimental cerebral ischemia-reperfusion.J Cereb Blood Flow Metab. 2024 Jul 28:271678X241264401. doi: 10.1177/0271678X241264401. Online ahead of print. J Cereb Blood Flow Metab. 2024. PMID: 39068534 Free PMC article.
-
MMP-9 upregulation may predict hemorrhagic transformation after endovascular thrombectomy.Front Neurol. 2024 May 9;15:1400270. doi: 10.3389/fneur.2024.1400270. eCollection 2024. Front Neurol. 2024. PMID: 38798706 Free PMC article.
References
-
- Adams HP, Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007;38:1655–1711. [published corrections appear in Stroke. 2007;38:e38 and Stroke. 2007;38:e96]. - PubMed
-
- del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Jr, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gresss D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78–86. - PubMed
-
- Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42:976–982. - PubMed
-
- Yamaguchi T, Hayakawa T, Kikuchi H, the Japanese Thrombolysis Study Group . Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double blind trial. In: del Zoppo GJ, Mori E, Hacke W, editors. Thrombolytic Therapy in Acute Ischemic Stroke II. Springer-Verlag; Heidelberg, Germany: 1993. pp. 59–65.
-
- Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
